Gena Wang
Stock Analyst at Barclays
(2.15)
# 2,564
Out of 4,814 analysts
198
Total ratings
34.85%
Success rate
-5.55%
Average return
Main Sectors:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLUE bluebird bio | Maintains: Overweight | $40 → $8 | $4.15 | +92.77% | 11 | Mar 31, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $63 → $57 | $26.67 | +113.72% | 2 | Feb 28, 2025 | |
| VIR Vir Biotechnology | Maintains: Overweight | $26 → $31 | $5.47 | +467.25% | 6 | Feb 28, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $55 → $26 | $7.27 | +257.88% | 7 | Feb 28, 2025 | |
| MRNA Moderna | Downgrades: Equal-Weight | $111 → $45 | $24.73 | +82.00% | 8 | Feb 18, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $56 | $37.76 | +48.31% | 15 | Feb 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $435 → $467 | $489.10 | -4.52% | 16 | Feb 11, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $5 → $3 | $1.29 | +133.46% | 9 | Dec 13, 2024 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $45 → $56 | $47.45 | +18.02% | 14 | Dec 3, 2024 | |
| KOD Kodiak Sciences | Maintains: Underweight | $3 → $4 | $2.84 | +40.85% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $9 | $0.71 | +1,174.43% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $5 | $1.43 | +249.65% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $8 | $7.39 | +8.25% | 9 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $234.75 | +40.15% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $59.12 | +45.47% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $15 | $2.56 | +487.08% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $226 → $203 | $53.79 | +277.39% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $31 | $16.25 | +90.77% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $5.96 | +738.93% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $35.64 | +127.27% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $51 | $28.32 | +80.08% | 9 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.06 | +1,370.59% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $32.77 | +186.85% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $11.54 | -22.01% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $10.51 | +137.87% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $5.43 | +231.49% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $8 | $6.73 | +18.87% | 1 | Nov 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $2.86 | +214.69% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $4.84 | +5,581.82% | 1 | Jan 6, 2017 |
bluebird bio
Mar 31, 2025
Maintains: Overweight
Price Target: $40 → $8
Current: $4.15
Upside: +92.77%
Avidity Biosciences
Feb 28, 2025
Maintains: Overweight
Price Target: $63 → $57
Current: $26.67
Upside: +113.72%
Vir Biotechnology
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.47
Upside: +467.25%
Intellia Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $7.27
Upside: +257.88%
Moderna
Feb 18, 2025
Downgrades: Equal-Weight
Price Target: $111 → $45
Current: $24.73
Upside: +82.00%
CRISPR Therapeutics AG
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $55 → $56
Current: $37.76
Upside: +48.31%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $489.10
Upside: -4.52%
Editas Medicine
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $1.29
Upside: +133.46%
PTC Therapeutics
Dec 3, 2024
Maintains: Equal-Weight
Price Target: $45 → $56
Current: $47.45
Upside: +18.02%
Kodiak Sciences
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $2.84
Upside: +40.85%
Nov 14, 2024
Maintains: Overweight
Price Target: $3 → $9
Current: $0.71
Upside: +1,174.43%
Nov 5, 2024
Maintains: Overweight
Price Target: $7 → $5
Current: $1.43
Upside: +249.65%
Nov 5, 2024
Maintains: Equal-Weight
Price Target: $7 → $8
Current: $7.39
Upside: +8.25%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $234.75
Upside: +40.15%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $59.12
Upside: +45.47%
Aug 14, 2024
Maintains: Overweight
Price Target: $18 → $15
Current: $2.56
Upside: +487.08%
Aug 8, 2024
Maintains: Overweight
Price Target: $226 → $203
Current: $53.79
Upside: +277.39%
Aug 7, 2024
Maintains: Equal-Weight
Price Target: $33 → $31
Current: $16.25
Upside: +90.77%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $5.96
Upside: +738.93%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $35.64
Upside: +127.27%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $45 → $51
Current: $28.32
Upside: +80.08%
Apr 15, 2024
Initiates: Overweight
Price Target: $45
Current: $3.06
Upside: +1,370.59%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $32.77
Upside: +186.85%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $11.54
Upside: -22.01%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $10.51
Upside: +137.87%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $5.43
Upside: +231.49%
Nov 17, 2021
Maintains: Overweight
Price Target: $24 → $8
Current: $6.73
Upside: +18.87%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $2.86
Upside: +214.69%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $4.84
Upside: +5,581.82%